natgillin/translations-raw huggingface dataset:
The first co-primary efficacy outcome was the time to the first occurrence of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary efficacy outcome was the time to the first occurrence of any of the first co-primary events, or revascularisation procedure (coronary, carotid, or peripheral), or hospitalisation for heart failure.
Prvi primarni izid učinkovitosti je bil čas do prvega pojava srčno-žilne smrti, neusodnega miokardnega infarkta (MI), neusodne možganske kapi, drugi primarni izid učinkovitosti pa je bil čas do prvega pojava katerega koli od prvih primarnih dogodkov, do revaskularizacijskega posega (koronarni,
Contents of the pack and other information What ABASAGLAR contains
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo ABASAGLAR
Insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH.
Insulin glargin je analog humanega insulina, pripravljen tako, da je pri nevtralnem pH slabo topen.
More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose.
Hujše primere s komo, generaliziranimi krči ali nevrološko prizadetostjo je mogoče zdraviti z glukagonom intramuskularno ali subkutano oz. s koncentrirano glukozo intravensko.
- You may have dust, food, or liquid inside the pen.
- morda se je v notranjosti peresnika nabral prah, hrana ali tekočina.
• Do not store the pen with the needle attached to prevent leaking, blocking the needle, and air from entering the pen.
Peresnika ne shranjujte s privito iglo, da preprečite puščanje, zamašitev igle in vstop zraka v peresnik.
Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see section 4.4).
Prilagoditev odmerka je lahko potrebna tudi, če se npr. spremeni bolnikova telesna masa, način življenja ali čas apliciranja insulina, ali se pojavijo kakšne druge okoliščine, ki povečajo nagnjenost k hipoglikemiji ali hiperglikemiji (glejte poglavje 4.4).
Each cartridge contains 3 mL of solution for injection (equivalent to 300 units) and they are available in packs of 5 and 10 cartridges.
Vsak vložek vsebuje 3 ml raztopine za injiciranje (kar ustreza 300 enotam), na voljo pa so v pakiranjih po 5 in 10 vložkov.
Due to more sustained basal insulin supply with insulin glargine, less nocturnal but more early morning hypoglycaemia can be expected.
Zaradi enakomernejšega sproščanja bazalnega insulina je pri insulinu glargin mogoče pričakovati manj nočnih, a več zgodnjih jutranjih hipoglikemij.
In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults.
Navadno so neželeni učinki pri otrocih in mladostnikih starih < 18 let podobni neželenim učinkom pri odraslih.
3 mL solution in a cartridge (type 1 colourless glass) with a plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl rubber) with aluminium seal.
3 ml raztopine v vložku (iz brezbarvnega stekla tipa 1) z batom (iz halobutilne gume) in zaporno ploščico (iz poliizoprenskega laminata in halobutilne gume) z aluminijasto zaporko.
What ABASAGLAR is and what it is used for
Kaj je zdravilo ABASAGLAR in za kaj ga uporabljamo
Thirst, increased need to urinate, tiredness, dry skin, reddening of the face, loss of appetite, low blood pressure, fast heartbeat, and glucose and ketone bodies in urine.
Žeja, pogostejše siljenje na vodo, utrujenost, suha koža, pordelost obraza, izguba teka, nizek krvni tlak, hitro bitje srca ter glukoza in ketoni v urinu.
• Pull the needle out of your skin.
Izvlecite iglo iz kože.
In use
V uporabi
• Skin changes at the injection site
• Spremembe kože na mestu injiciranja
The total therapeutic insulin concentration (insulin glargine and its metabolites) found in type 1 diabetic patients was markedly lower than what would be required for a half maximal occupation of the IGF-1 receptor and the subsequent activation of the mitogenic-proliferative pathway initiated by the IGF-1 receptor.
Celotna terapevtska koncentracija insulina (insulina glargina in njegovih presnovkov) je bila pri bolnikih s sladkorno boleznijo tipa 1 bistveno manjša od koncentracije, potrebne za polovično največjo zasedenost receptorjev za IGF-1 in posledično aktivacijo mitogeno-proliferacijske poti, ki jo sproža receptor za IGF-1.
The medicinal product may be stored for a maximum of 28 days up to 30°C and away from direct heat or direct light.
Zdravilo lahko shranjujete največ 28 dni pri temperaturi do 30 °C in zaščiteno pred neposredno toploto ali svetlobo.
One hundred forty three of the patients treated with insulin glargine in this study continued treatment with insulin glargine in an uncontrolled extension study with mean duration of follow-up of 2 years.
Sto triinštirideset (143) bolnikov, ki so v tej študiji uporabljali insulin glargin, je zdravljenje z njim nadaljevalo v nekontrolirani podaljšani študiji, v kateri je povprečno spremljanje trajalo 2 leti.
Correspondingly, the incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine / lispro group vs. 52 % in the NPH / regular group.
Ustrezno so bile incidence nočne hipoglikemije 32-% v skupini z insulinom glargin/insulinom lispro, v skupini z insulinom NPH/redni skupini pa 52-%.
Immediately take about 10 to 20 g sugar, such as glucose, sugar cubes or a sugar-sweetened beverage.
Nemudoma zaužijte približno 10 do 20 gramov sladkorja, v obliki glukoze,
Do not mix ABASAGLAR with any other insulins or medicines.
Ne mešajte zdravila ABASAGLAR z nobenim drugim insulinom ali zdravili.
The pharmacokinetic and pharmacodynamic findings indicate that the effect of the subcutaneous injection with insulin glargine is principally based on exposure to M1. Insulin glargine and the metabolite M2 were not detectable in the vast majority of subjects and, when they were detectable their concentration was independent of the administered dose of insulin glargine.
Farmakokinetični in farmakodinamski izsledki kažejo, da učinek subkutano injiciranega insulina glargin temelji predvsem na izpostavljenosti presnovku M1. Insulin glargin in presnovek M2 pri veliki večini preiskovancev nista bila zaznavna; če sta bila zaznavna, pa njuna koncentracija ni bila odvisna od uporabljenega odmerka insulina glargin.
Rarely, insulin may cause sodium retention and oedema particularly if previously poor metabolic control is improved by intensified insulin therapy.
Redko lahko insulin povzroči zadrževanje natrija in edeme, še zlasti, če intenzivirano insulinsko zdravljenje izboljša presnovno urejenost, ki je bila prej slaba.
Insulin glargine was administered once daily at bedtime and NPH human insulin was administered once or twice daily.
Insulin glargin so uporabljali enkrat na dan pred spanjem, humani insulin NPH pa enkrat ali dvakrat na dan.
Prolonged or severe hypoglycaemic episodes may be life-threatening.
Dolgotrajne ali hude hipoglikemije so lahko smrtno nevarne.
Participants were randomised (1:1) to receive insulin glargine (n=6,264), titrated to reach FPG ≤95 mg/dL (5.3 mM), or standard care (n=6,273).
Preiskovanci so po randomizaciji (1:1) prejemali insulin glargin (n=6264), titriran tako, da so dosegli FPG ≤95 mg/dl (5,3 mM), ali standardno zdravljenje.
Figure 1 above shows the activity profiles over time of insulin glargine and NPH insulin.
Slika 1 zgoraj prikazuje časovni potek delovanja insulina glargin in insulina NPH.
If you forget to use ABASAGLAR
Če ste pozabili vzeti zdravilo ABASAGLAR
Before using ABASAGLAR solution for injection in pre-filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6).
Pred uporabo zdravila ABASAGLAR raztopina za injiciranje v napolnjenem injekcijskem peresniku morate pozorno prebrati Navodila za uporabo na vloženem lističu (glejte poglavje 6.6).
Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia.
Pentamidin lahko povzroči hipoglikemijo, ki ji včasih sledi hiperglikemija.
If you notice signs of your blood sugar being too low (hypoglycaemia), take the action to increase your blood sugar levels inmediately.
Če opazite znake prenizkega krvnega sladkorja (hipoglikemije), takoj ukrepajte, da si zvišate dvignete koncentracijo krvnega sladkorja.
• Store the pen you are currently using at room temperature [below 30 ° C] and away from heat and light.
• Peresnik, ki ga trenutno uporabljate, shranjujte pri sobni temperaturi [do 30 °C] in zaščitenega pred toploto in svetlobo.
Instead, regular insulin administered intravenously is recommended in such cases.
V takšnih primerih je treba uporabiti običajni insulin, apliciran intravensko.
Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or using machines).
Ne pozabite na to v okoliščinah, v katerih bi lahko ogrozili sebe in druge (kot sta vožnja avtomobila ali uporaba strojev).
At baseline, participants had a median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9 to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care group throughout the duration of follow-up.
Ob izhodišču so imeli preiskovanci mediano vrednost HbA1c 6,4 %, mediane vrednosti HbA1c med zdravljenjem pa so bile med 5,9 in 6,4 % v skupini z insulinom glargin in med 6,2 in 6,6 % v skupini s standardnim zdravljenjem ves čas spremljanja, Stopnji hude hipoglikemije (prizadeti preiskovanci na 100
In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles.
V redkih primerih zdravljenje z insulinom povzroči tudi prehodno zadrževanje vode v telesu in posledično otekanje meč in gležnjev.
In rare cases, the presence of such insulin antibodies may necessitate adjustment of the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see section 5.1).
V redkih primerih je zaradi obstoja takšnih protiteles proti insulinu treba prilagoditi odmerek insulina, da bi odpravili nagnjenost k hiperali hipoglikemiji (glejte poglavje 5.1).
In a clinical study, symptoms of hypoglycaemia or counter-regulatory hormone responses were similar after intravenous insulin glargine and human insulin both in healthy volunteers and patients with type 1 diabetes.
V klinični študiji so bili simptomi hipoglikemije in protiregulacijski hormonski odzivi po intravenski uporabi insulina glargin in humanega insulina pri zdravih prostovoljcih in bolnikih z diabetesom tipa 1 podobni.
How to store ABASAGLAR Contents of the pack and other information
Shranjevanje zdravila ABASAGLAR Vsebina pakiranja in dodatne informacije
• Check the number in the dose window
Preverite številko v okencu za prikaz odmerka
This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar).
Če ste prenehali jemati zdravilo ABASAGLAR To lahko vodi v hudo hiperglikemijo (zelo visok krvni sladkor) in ketoacidozo (kopičenje kisline v krvi, ker telo presnavlja maščobe namesto sladkorja).
- The dose knob clicks as you turn it. - DO NOT dial your dose by counting the clicks because you may dial the wrong dose.
- NE nastavite svojega odmerka s štetjem klikov, saj bi lahko nastavili napačen odmerek.
• Prepare your skin as recommended by your healthcare professional.
Pripravite kožo, kot vam je to priporočil vaš zdravnik.
- You should use a new needle for each injection and repeat the priming step.
- Za vsako injiciranje morate uporabiti novo iglo in ponoviti aktivacijo peresnika.
Before injection remove any air bubbles (see instructions for using the pen).
Pred injiciranjem odstranite vse zračne mehurčke (glejte navodila za uporabo peresnika).
Insulin glargine did not alter the relative risk for CV disease and CV mortality when compared to standard of care.
Insulin glargin v primerjavi s standardnim zdravljenjem ni spremenil relativnega tveganja za srčnožilno bolezen in srčno-žilno smrtnost.
When switching from a treatment regimen with an intermediate or long-acting insulin to a regimen with ABASAGLAR, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fastacting insulin analogues or the dose of oral antidiabetic medicinal products).
Pri prehodu s srednjedolgo- ali dolgodelujočega insulina na zdravljenje z zdravilom ABASAGLAR utegneta biti potrebna sprememba odmerka bazalnega insulina in prilagoditev sočasnega antidiabetičnega zdravljenja (odmerek in časovni razpored dodatnih običajnih insulinov ali hitrodelujočih insulinskih analogov oz. odmerek peroralnih antidiabetikov).
ABASAGLAR with alcohol
- pitje alkohola,
Adolescents and children aged 2 years and older The safety and efficacy of insulin glargine have been established in adolescents and children aged 2 years and older (see section 5.1).
Varnost in učinkovitost insulina glargin sta bili ugotovljeni pri mladostnikih in otrocih, starih 2 leti in starejših (glejte poglavje 5.1).
The prolonged duration of action of insulin glargine is dependent on its injection into subcutaneous tissue.
Podaljšano delovanje insulina glargin je povezano s tem, da je injiciran v podkožno tkivo.
Severe allergic reactions (rare, may affect up to 1 in 1,000 people) - the signs may include large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating.
Hude alergijske reakcije (redke, lahko se pojavijo pri največ 1 od 1.000 bolnikov) - znaki lahko vključujejo obsežne kožne reakcije (izpuščaj in srbenje po celem telesu), hudo oteklino kože ali sluznic
Hypoglycaemia (very common), in general the most frequent adverse reaction of insulin therapy, may occur if the insulin dose is too high in relation to the insulin requirement (see section 4.4).
Hipoglikemija (zelo pogosta), na splošno najpogostejši neželeni učinek zdravljenja z insulinom, se lahko pojavi, če je odmerek insulina prevelik glede na potrebo po insulinu (glejte poglavje 4.4).
Do not store ABASAGLAR next to the freezer compartment or a freezer pack.
Zdravila ABASAGLAR ne shranjujte v bližini zamrzovalnega razdelka ali zamrzovalnega vložka.
Examples of symptoms that tell you that your blood sugar level is falling too much or too fast: sweating, clammy skin, anxiety, fast heart beat, high blood pressure, palpitations and irregular heartbeat.
Primeri simptomov, ki vam povedo, da se je krvni sladkor znižal preveč ali prehitro, so: znojenje, vlažna in lepljiva koža, tesnoba, hiter srčni utrip, visok krvni tlak, razbijanje srca in nereden srčni utrip.
In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are either too low or too high.
V vsakem primeru utegne biti potrebna prilagoditev odmerka insulina, da bi se izognili prenizki ali previsoki koncentraciji krvnega sladkorja.
Factors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may necessitate dose adjustment.
V primeru dejavnikov, ki povečujejo nagnjenost k hipoglikemiji, mora biti nadzor posebej natančen; potrebna utegne biti prilagoditev odmerka.
Problems with the insulin pen?
Imate težave z insulinskim peresnikom?
Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:
Vaš zdravnik bo, glede na vaš način življenja, izvide meritev vašega krvnega sladkorja (glukoze) in prejšnjo uporabo insulina:
How to recognise your ABASAGLAR KwikPen:
Kako prepoznati peresnik ABASAGLAR KwikPen:
The ORIGIN (Outcome Reduction with Initial Glargine INtervention) study was a multicenter, randomised, 2x2 factorial design study conducted in 12,537 participants at high cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus treated with ≤1 antidiabetic oral agent (88% of participants).
Študija ORIGIN (izboljšanje izida z začetnim dajanjem glargina) je bila multicentrična, randomizirana študija s faktorskim načrtom, opravljena na 12.537 preiskovancih z velikim srčno-žilnim (SŽ) tveganjem z moteno glukozo na tešče (IFG) ali moteno glukozno toleranco (IGT) (12 % preiskovancev) ali diabetesom tipa 2, zdravljenim z ≤1 peroralnim antidiabetikom (88 %
The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation.
Znaki lahko vključujejo pordelost, nenavadno močno bolečino pri injiciranju, srbenje, koprivnico, otekanje ali vnetje.
If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet).
Če imate prenizek krvni sladkor (hipoglikemijo), upoštevajte navodila za ravnanje v primeru hipoglikemije (glejte okvir na koncu tega navodila).
KwikPen Multipack: 10 (2 packs of 5) pens of 3 mL.
Peresnik KwikPen Večje pakiranje: 10 (2 x 5) peresnikov po 3 ml
The prolonged effect of subcutaneous insulin glargine may delay recovery from hypoglycaemia.
Podaljšani učinek subkutanega insulina glargin lahko upočasni okrevanje po hipoglikemiji.
The instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.
Navodila za uporabo peresnika morate natančno upoštevati, ko vstavljate vložek, pritrjujete iglo in dajete injekcijo insulina.
With improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dose regimen may become necessary.
Zaradi boljše urejenosti presnove in večje občutljivosti za insulin utegne biti potrebna nadaljnja prilagoditev odmerka.
You may need to talk about: - the availability of your insulin in the country you are visiting, - supplies of insulin etc.
Med vprašanji, o katerih se boste morali pogovoriti, so: - dosegljivost vašega insulina v državi, v katero se odpravljate, - zaloge insulina itd., - pravilno shranjevanje insulina med potovanjem,
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose lowering effect of insulin.
Zaviralci adrenergičnih receptorjev beta, klonidin, litijeve soli ali alkohol lahko učinek znižanja glukoze v krvi pri insulinu bodisi stopnjujejo ali oslabijo.
These cartridges are for use with a Lilly 3 mL pen only.
Ti vložki so namenjeni izključno uporabi s 3-ml peresnikom Lilly.
Injection sites must be rotated within a given injection area from one injection to the next.
Mesto injiciranja na posameznem predelu je treba od injekcije do injekcije krožno menjati.
The rates of severe hypoglycaemia (affected participants per 100 participant years of exposure) were 1.05 for insulin glargine and 0.30 for standard care group and the rates of confirmed non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard care group.
udeleženskih let izpostavljenosti) sta bili 1,05 v skupini z insulinom glargin in 0,30 v skupini s standardnim zdravljenjem, stopnji potrjene hipoglikemije, ki ni bila huda, pa sta bili 7,71 v skupini z insulinom glargin in 2,44 v skupini s stanrdadnim zdravljenjem.
• Wipe the rubber seal with a swab.
• Gumijasto zaporko obrišite z zložencem.
• Change (rotate) your injection site for each injection.
• Za vsako injiciranje spremenite (rotirajte) mesto injiciranja.
Do not dilute it. Mixing or diluting may change the action of ABASAGLAR.
Ne redčite ga. Mešanje ali redčenje lahko spremeni delovanje zdravila ABASAGLAR.
Do not use if it is cloudy, coloured, or has particles or clumps in it.
Ne uporabljajte zdravila, če je motno, obarvano ali če vsebuje delce ali grudice.
In vitro studies indicate that the affinity of insulin glargine and its metabolites M1 and M2 for the human insulin receptor is similar to the one of human insulin.
Študije in vitro kažejo, da je afiniteta insulina glargina in njegovih presnovkov M1 in M2 za človeške insulinske receptorje podobna afiniteti humanega insulina.
• To prime your pen, turn the dose knob to select 2 units.
• Zavrtite gumb za odmerjanje tako, da izberete 2 enoti.
Monitor your blood glucose as instructed by your healthcare professional.
Spremljajte raven glukoze v krvi, kot vam je naročil zdravnik.
How to handle ABASAGLAR KwikPen
Kako ravnati s peresnikom ABASAGLAR KwikPen
In patients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Bolnikom z okvaro jeter se lahko potreba po insulinu zmanjša zaradi zmanjšane zmožnosti za glukoneogenezo in zmanjšane presnove insulina.
Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
Zdravljenje diabetesa mellitusa pri odraslih, mladostnikih in otrocih, starih 2 leti in več.
The instructions for using the insulin pen are provided with your insulin pen.
Navodila za uporabo insulinskega peresnika so priložena vašemu insulinskemu peresniku.
How to use ABASAGLAR
Kako uporabljati zdravilo ABASAGLAR
ABASAGLAR is available in packs containing 5 pre-filled pens and in multipacks comprising 2 cartons, each containing 5 pre-filled pens.
Na voljo so pakiranja po 5 napolnjenih peresnikov in večja pakiranja , ki vsebujejo 2 pakiranji, eno pakiranje vsebuje 5 napolnjenih peresnikov.
The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
Temeljno delovanje insulina, tudi insulina glargin, je uravnavanje presnove glukoze.
No metabolic effects of ingested insulin glargine on the breast-fed newborn/infant are anticipated since insulin glargine as a peptide is digested into amino acids in the human gastrointestinal tract.
Presnovnih učinkov zaužitega insulina glargin na dojenega novorojenčka/dojenčka ni pričakovati, ker se insulin glargin kot peptid v človeških prebavilih prebavi v aminokisline.
Cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for development of cardiac heart failure.
Pri uporabi kombinacije pioglitazona in inzulina poročajo o primerih srčnega popuščanja, predvsem pri bolnikih z dejavniki tveganja za razvoj srčnega popuščanja.
Serious hypoglycaemia may cause brain damage and may be life-threatening.
Huda hipoglikemija lahko povzroči poškodbo možganov in je lahko smrtno nevarna.
If you think you may have a problem with ABASAGLAR KwikPen, consult your doctor, pharmacist or nurse.
Če se vam zdi, da imate težave s peresnikom ABASAGLAR KwikPen, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Make sure that neither alcohol nor other disinfectants or other substances contaminate the insulin.
Poskrbeti morate, da insulina ne bodo onesnažili alkohol, druga dezinfekcijska sredstva ali kakšne druge snovi.
A number of substances affect glucose metabolism and may require dose adjustment of insulin glargine.
Na presnovo glukoze vplivajo številna zdravila in potrebna utegne biti prilagoditev odmerka insulina glargin.
Switch from twice daily NPH insulin to ABASAGLAR To reduce the risk of nocturnal and early morning hypoglycaemia, patients who are changing their basal insulin regimen from a twice daily NPH insulin to a once daily regimen with ABASAGLAR should reduce their daily dose of basal insulin by 20-30 % during the first weeks of treatment.
Prehod z insulina NPH dvakrat na dan na zdravilo ABASAGLAR Bolniki, ki z insulina NPH dvakrat na dan preidejo na zdravilo ABASAGLAR enkrat na dan, morajo za zmanjšanje nevarnosti nočne in zgodnje jutranje hipoglikemije dnevni odmerek bazalnega insulina v prvih tednih zdravljenja zmanjšati za 20 do 30%.
• Unscrew the capped needle and dispose of it as directed by your healthcare professional.
Odvijte iglo s pokrovčkom in jo zavrzite v skladu z navodili vašega zdravstvenega delavca.
Dose Knob with green ring
Gumb za odmerjanje z zelenim obročem
ABASAGLAR").
preiskovancev).
• Push the capped needle straight onto the pen and twist the needle on until it is tight.
• Potisnite iglo s pokrovčkom naravnost v peresnik in trdno privijte iglo.